Overview

* Ionis Q3 2025 revenue grows 17% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, reflecting strong operational performance

* Company raises 2025 financial guidance due to strong revenue performance

Outlook

* Ionis raises 2025 revenue guidance to $875-900 mln from $825-850 mln

* TRYNGOLZA 2025 sales guidance increased to $85-95 mln from $75-80 mln

* Ionis expects cash flow breakeven by 2028

Result Drivers

* TRYNGOLZA SALES - Nearly 70% increase in TRYNGOLZA sales over the prior quarter, contributing to revenue growth

* ROYALTY REVENUE - Higher royalty revenue contributed to year-over-year revenue increase

* UPFRONT PAYMENT - $280 mln upfront payment from Ono Pharmaceutical for sapablursen license boosted revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $157 mln $130.92

Revenue mln (18

Analysts

)

Q3 EPS Beat -$0.80 -$1.23

(17

Analysts

)

Q3 Net -$129

Income mln

Q3 Beat -$129 -$196.11

Adjusted mln mln (17

Operatin Analysts

g Income )

Q3 $286 mln

Adjusted

Operatin

g

Expenses

Q3 $317 mln

Operatin

g

Expenses

Q3 -$160

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc ( IONS ) is $78.00, about 5.7% above its October 28 closing price of $73.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)